Special authorization, prior authorization, limited use, and exception workflows are not interchangeable

A practical distinction between authorization pathways that are often described with the same shorthand at the counter.

The phrase “needs authorization” hides several different processes. A claim may require public-plan exceptional access, private-plan prior authorization, limited-use criteria, step-therapy evidence, dose-specific approval, or sponsor-level exception handling. Each pathway has a different owner and a different remedy.

The pharmacy should identify which pathway applies before sending the patient back to the prescriber. A prescriber can complete a clinical form, but cannot usually fix an incorrect carrier, a plan-sponsor exclusion, a missing dependant status update, or a private plan that requires the cardholder to initiate the request.

Public authorization is usually rule-based

Public programs tend to publish criteria for exceptional access, limited use, or special authorization. The question is whether the patient and drug meet the published criteria and whether the required form or code has been submitted. The pharmacy may be able to see the online claim result, but the clinical decision may occur in a separate review process.

Private authorization may be plan-specific

Private plans can vary by sponsor. Two patients under the same insurer brand may have different authorization requirements because their employers purchased different benefit designs. A rejection that says prior authorization required does not necessarily mean the insurer rejects the drug for everyone. It may mean this sponsor requires review at this dose, quantity, age, diagnosis, or sequence of therapy.

• Identify the payer and plan type before naming the form.
• Check whether approval is attached to the drug, DIN, dose, quantity, or patient status.
• Confirm whether the prescriber, patient, cardholder, or pharmacy must initiate the request.
• Do not assume that a previous approval covers a new dose or formulation.
• Record the date the authorization requirement was communicated.

What the pharmacy can and cannot solve

The pharmacy can often identify the pathway, provide the rejection wording, direct the patient or prescriber to the correct form, and document the interim plan. The pharmacy cannot manufacture clinical criteria, backdate approval, or bypass a hard authorization requirement with an intervention code unless the plan explicitly provides that route.

This is why FRx separates rejection-code triage from authorization guidance. The same on-screen phrase may require a prescriber form, a patient call, a manual submission, or no pharmacy-side action at all.

FRx guide page · Static editorial reference · Last reviewed 2026-05-02